Accelr8 Technology Corporation (NYSE Amex: AXK) today announced that it completed the sale of a non-exclusive license for its proprietary OptiChem® bio-coatings to an innovative, public diagnostics company. The licensee is paying $1,865,000 over four annual escalating payments and intends to use OptiChem® in its disposable diagnostic devices.
“We are very pleased to have a diagnostics innovator select OptiChem after comparing a number of competing coatings. Once again, OptiChem offered superior technical attributes that improve total system performance at advantageous costs with scalable manufacturing.”
According to David Howson, Accelr8's president, "We are very pleased to have a diagnostics innovator select OptiChem after comparing a number of competing coatings. Once again, OptiChem offered superior technical attributes that improve total system performance at advantageous costs with scalable manufacturing."
"The licensee's products do not compete with our BACcel™ rapid diagnostic system, but complement it in different applications. This license expands our corporate presence in the clinical diagnostic segment. It also opens future licensing opportunities for additional, complementary new diagnostic applications that take advantage of the optimization we've achieved with OptiChem's development," he concluded.
Mediterranean diet success looks different for women and men, study of 4,000 adults reveals